International Health Management Associates, Inc., Schaumburg, IL, USA.
Diagn Microbiol Infect Dis. 2011 Aug;70(4):507-11. doi: 10.1016/j.diagmicrobio.2011.03.021.
Escherichia coli is the most important uropathogen. The Study for Monitoring Antimicrobial Resistance Trends program collected 1643 E. coli isolates in 2009-2010 from urinary tract infection (UTI) specimens of hospitalized patients in countries worldwide. Ertapenem and imipenem were the most active agents tested, inhibiting >98% of all E. coli phenotypes. Overall, 17.9% of isolates were extended-spectrum beta-lactamase (ESBL) producers. The highest ESBL rate was from the Asia/Pacific region (27.7%). Amikacin and piperacillin-tazobactam achieved 90% inhibition levels only for ESBL-negative isolates. Ciprofloxacin and levofloxacin were not effective for ESBL-positive isolates, with only 14.6% and 15.9% susceptible, respectively. These observations highlight the need for continued monitoring of susceptibility of E. coli isolated from hospitalized patients with UTIs.
大肠埃希菌是最重要的尿路病原体。监测抗菌药物耐药趋势研究项目在 2009 至 2010 年期间，从全球住院患者的尿路感染（UTI）标本中收集了 1643 株大肠埃希菌分离株。厄他培南和亚胺培南是检测到的最有效的药物，抑制了所有大肠埃希菌表型的>98%。总的来说，17.9%的分离株是产超广谱β-内酰胺酶（ESBL）的。ESBL 率最高的是亚太地区（27.7%）。阿米卡星和哌拉西林-他唑巴坦仅对 ESBL 阴性分离株达到 90%的抑制水平。环丙沙星和左氧氟沙星对 ESBL 阳性分离株无效，敏感性分别为 14.6%和 15.9%。这些观察结果强调了需要继续监测住院尿路感染患者分离的大肠埃希菌的敏感性。
